Drug Profile


Alternative Names: Growth hormone releasing peptide-1 - Atrix Laboratories

Latest Information Update: 11 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tulane University
  • Developer QLT USA
  • Class Oligopeptides
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cachexia; Nutrition disorders; Short stature

Most Recent Events

  • 01 Oct 2009 QLT USA has been acquired by Tolmar
  • 22 Nov 2004 Atrix Laboratories has been acquired by QLT
  • 24 Jun 2004 Phase-I clinical trials in Cachexia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top